Effect of the Consumption of a Fermented Milk on Common Infections in Adults Submitted to Multi-stressor Situation
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This multicentric, randomized, double-blind and controlled study aims to examine the effect of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel® = tested product) on the incidence of respiratory and gastro-intestinal common infectious diseases (cumulated number of infections during the intervention period: primary criteria), and on the Quality of Life in adults submitted to multi-stressor situation. Volunteers received either 200g/day of tested product (N=121) or control product (N=118) for 7-weeks.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 29 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
male and female aged 18-29 years
attending 7 weeks of firemen training school
a 19 to 29 kg/m2 body mass index
found medically healthy (in particular, free of respiratory and GI tract symptoms)
agreeing to a written informed consent, and who appreciates dairy products and multi-fruit flavour.
Subject who is not reading and writing French, or not understanding informed consent or study protocol
subject with allergy or hypersensitivity to milk proteins or dairy foods components (ex: lactose), or with any known food or respiratory allergy;
subject presenting a severe evolutive or chronic pathology (Ex: cancer, tuberculosis, Crohn disease, cirrhosis, multiple sclerosis, Type I diabetes…) or any past or actual health condition that may interfere with the outcome of the study (Ex: HIV, Chemotherapy, malabsorption, ulcer, celiac disease…)
subject having experienced any infectious disease during the last 7 days
subject with current diarrhoea or constipation
subject who is frequently using laxatives or who has been using laxatives during the week prior his participation to the study
subject who was under artificial nutrition, had gastro-intestinal surgery or any intervention requiring general anaesthesia the last 2 months prior to his participation to the study
subject with special medicated diet (obesity, anorexia, metabolic pathology, nutritional complementation…) or with eating disorders (anorexia, bulimia, alcoholism…)
subject currently receiving, or who has received during the last months, systemic treatment or topical treatment likely to interfere with evaluation of the study parameters: antibiotics, antiseptics,antifungal, corticoids, vaccines, anti-histaminic molecules, non-corticoid anti-inflammatory substances, immunosuppressant treatment…
subject already enrolled in another clinical study, or currently under an exemption period from a previous study
female subject who is currently pregnant or breast-feeding, or willing to become pregnant during the 2 coming months after enrolment in the study
subject in a situation which in the investigator's opinion could interfere with optimal participation in the present study or could constitute a special risk for the subject
Probiotic - Lactobacillus casei DN-114 001 - dairy product -
infections - firemen
Common infectious diseases, occuring in healthy subjects,
including upper respiratory tract infections (defined as
rhinopharyngitis, sore throat, sinusitis and otitis)
lower respiratory tract infections (defined as bronchitis
pneumopathy and flu and flu-like syndromes)
gastrointestinal tract infection defined as gastroenteritis